[
    [
        {
            "time": "2020-01-13",
            "original_text": "Brodsky & Smith, LLC Announces an Investigation of Dermira, Inc. - (Nasdaq:DERM)",
            "features": {
                "keywords": [
                    "Investigation",
                    "Dermira",
                    "Shareholder"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Brodsky & Smith, LLC Announces an Investigation of Dermira, Inc. - (Nasdaq:DERM)",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-01-13",
            "original_text": "Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dermira, Inc. to Eli Lilly and Company is Fair to Shareholders",
            "features": {
                "keywords": [
                    "Investigation",
                    "Dermira",
                    "Eli Lilly",
                    "Sale"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Dermira, Inc. to Eli Lilly and Company is Fair to Shareholders",
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2020-01-13",
            "original_text": "Glaxo Files Marketing Application for Fostemsavir in Europe",
            "features": {
                "keywords": [
                    "Glaxo",
                    "Fostemsavir",
                    "Marketing Application"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Glaxo Files Marketing Application for Fostemsavir in Europe",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-01-13",
            "original_text": "Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate",
            "features": {
                "keywords": [
                    "Lilly",
                    "Dermira",
                    "Acquisition",
                    "Phase III"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Lilly to Buy Dermira for $1.1B, Add Phase III Eczema Candidate",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 10,
                "Impact": 10,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2020-01-13",
            "original_text": "Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?",
            "features": {
                "keywords": [
                    "Invesco",
                    "Defensive Equity ETF",
                    "Investing"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "finance"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Should Invesco Defensive Equity ETF (DEF) Be on Your Investing Radar?",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-01-13",
            "original_text": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?",
            "features": {
                "keywords": [
                    "Invesco",
                    "Biotechnology",
                    "Genome ETF"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-01-13",
            "original_text": "Tyvyt速 (Sintilimab Injection) Combined with ALIMTA速 (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC",
            "features": {
                "keywords": [
                    "Tyvyt",
                    "Sintilimab",
                    "Phase 3",
                    "Primary Endpoint"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Tyvyt速 (Sintilimab Injection) Combined with ALIMTA速 (Pemetrexed) and Platinum Met Predefined Primary Endpoint in Phase 3 ORIENT-11 Study as First-Line Therapy in Nonsquamous NSCLC",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]